University of Kentucky

UKnowledge
Radiation Medicine Faculty Publications

Radiation Medicine

10-2017

Randomized Phase II Study Comparing Prophylactic Cranial
Irradiation Alone to Prophylactic Cranial Irradiation and
Consolidative Extracranial Irradiation for Extensive-Disease Small
Cell Lung Cancer (ED SCLC): NRG Oncology RTOG 0937
Elizabeth M. Gore
Froedtert & the Medical College of Wisconsin

Chen Hu
NRG Oncology Statistics and Data Management Center

Alexander Y. Sun
University Health Network, Canada

Daniel F. Grimm
Zablocki
Veterans
Administration
Medical
Center
Follow this
and additional
works at:
https://uknowledge.uky.edu/radmed_facpub
Part S.
of Ramalingam
the Diseases Commons, Oncology Commons, and the Radiology Commons
Suresh
Emory
University
Right click
to open a feedback form in a new tab to let us know how this document benefits you.

See next page
for additional authors
Repository
Citation
Gore, Elizabeth M.; Hu, Chen; Sun, Alexander Y.; Grimm, Daniel F.; Ramalingam, Suresh S.; Dunlap, Neal E.;
Higgins, Kristin A.; Werner-Wasik, Maria; Allen, Aaron M.; Iyengar, Puneeth; Videtic, Gregory M. M.; Hales,
Russell K.; McGarry, Ronald C.; Urbanic, James J.; Pu, Anthony T.; Johnstone, Candice A.; Stieber, Volker
W.; Paulus, Rebecca; and Bradley, Jeffrey D., "Randomized Phase II Study Comparing Prophylactic Cranial
Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extracranial Irradiation for
Extensive-Disease Small Cell Lung Cancer (ED SCLC): NRG Oncology RTOG 0937" (2017). Radiation
Medicine Faculty Publications. 20.
https://uknowledge.uky.edu/radmed_facpub/20

This Article is brought to you for free and open access by the Radiation Medicine at UKnowledge. It has been
accepted for inclusion in Radiation Medicine Faculty Publications by an authorized administrator of UKnowledge.
For more information, please contact UKnowledge@lsv.uky.edu.

Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to
Prophylactic Cranial Irradiation and Consolidative Extracranial Irradiation for
Extensive-Disease Small Cell Lung Cancer (ED SCLC): NRG Oncology RTOG 0937
Digital Object Identifier (DOI)
https://doi.org/10.1016/j.jtho.2017.06.015

Notes/Citation Information
Published in Journal of Thoracic Oncology, v. 12, issue 10, p. 1561-1570.
This manuscript version is made available under the CC‐BY‐NC‐ND 4.0 license
https://creativecommons.org/licenses/by-nc-nd/4.0/.
The document available for download is the author's post-peer-review final draft of the article.

Authors
Elizabeth M. Gore, Chen Hu, Alexander Y. Sun, Daniel F. Grimm, Suresh S. Ramalingam, Neal E. Dunlap,
Kristin A. Higgins, Maria Werner-Wasik, Aaron M. Allen, Puneeth Iyengar, Gregory M. M. Videtic, Russell K.
Hales, Ronald C. McGarry, James J. Urbanic, Anthony T. Pu, Candice A. Johnstone, Volker W. Stieber,
Rebecca Paulus, and Jeffrey D. Bradley

This article is available at UKnowledge: https://uknowledge.uky.edu/radmed_facpub/20

HHS Public Access
Author manuscript
Author Manuscript

J Thorac Oncol. Author manuscript; available in PMC 2018 October 01.
Published in final edited form as:
J Thorac Oncol. 2017 October ; 12(10): 1561–1570. doi:10.1016/j.jtho.2017.06.015.

Randomized Phase II Study Comparing Prophylactic Cranial
Irradiation Alone To Prophylactic Cranial Irradiation And
Consolidative Extra-Cranial Irradiation For Extensive Disease
Small Cell Lung Cancer (ED-SCLC): NRG Oncology RTOG 0937

Author Manuscript

Elizabeth M Gore, MD1, Chen Hu, PhD2,11, Alexander Y Sun, MD3, Daniel F Grimm, MS4,
Suresh S Ramalingam, MD5, Neal E Dunlap, MD6, Kristin A Higgins, MD5, Maria WernerWasik, MD7, Aaron M Allen, MD8, Puneeth Iyengar, MD, PhD9, Gregory M M Videtic, MD10,
Russell K Hales, MD11, Ronald C McGarry, MD12, James J Urbanic, MD13, Anthony T Pu,
MD14, Candice A Johnstone, MD1, Volker W Stieber, MD15, Rebecca Paulus, BS2, and
Jeffrey D Bradley, MD16
1Froedtert
2NRG

and the Medical College of Wisconsin, Milwaukee, WI

Oncology Statistics and Data Management Center, Philadelphia, PA

3University
4Zablocki

Health Network-Princess Margaret Hospital, Toronto, ON

Veterans Administration Medical Center, Milwaukee, WI

Author Manuscript

5Emory

University/Winship Cancer Institute, Atlanta, GA

6James

Graham Brown Cancer Center, University of Louisville, Louisville, KY

7Thomas
8Rabin
9UT

Jefferson University Hospital, Philadelphia, PA

Medical Center, Petah Tikva, Israel

Southwestern Medical Center, Dallas, TX

10Cleveland
11Johns

Hopkins University, Baltimore, MD

12University
13UC

Clinic Foundation, Cleveland, OH

of Kentucky, Lexington, KY

San Diego Moores Cancer Center, La Jolla, CA

Author Manuscript

14Sutter

Cancer Research Consortium, Sacramento, CA

Corresponding Author: Elizabeth Gore, MD, Professor of Radiation Oncology, Medical College of Wisconsin, 9200 W. Wisconsin
Avenue, Milwaukee, WI 53226, Office: 414-805-4465, Fax: 414-805-4354, egore@mcw.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Conflicts of interest: Dr. Hu reports grants from National Cancer Institute (NCI), during the conduct of the study. Dr. Ramalingam
reports serving on Advisory Boards for Amgen, Astra Zeneca, Abbvie, BMS, Lilly, Celgene, Genentech, and Novartis, outside the
submitted work. Ms. Paulus reports grants from National Cancer Institute (NCI) during the conduct of the study.

Gore et al.

Page 2

15Novant

Author Manuscript

Health Forsyth Medical Center accruals for Southeast Clinical Oncology Research
(SCOR) Consortium NCORP, Goldsboro, NC
16Washington

University, St. Louis, MO

Abstract
Introduction—RTOG-0937 is a randomized phase-II trial evaluating 1-year OS with PCI or PCI
plus consolidative radiation therapy (cRT) to intra-thoracic disease and extracranial metastases for
ED-SCLC.

Author Manuscript

Methods—Patients with 1–4 extracranial metastases were eligible after CR or PR to
chemotherapy. Randomization was to PCI or PCI+cRT to the thorax and metastases. Original
stratification included PR vs CR after chemotherapy and 1 vs 2–4 metastases; age < 65 vs ≥ 65
was added after an observed imbalance. PCI was 25GY/10 fractions. cRT was 45GY/15 fractions.
To detect an OS improvement from 30% to 45% with a 34% hazard reduction (HR=0·66) under a
0.1 type-1 error (1-sided) and 80% power, 154 patients were required.
Results—Ninety-seven patients were randomized between March, 2010 and February, 2015.
Eleven patients were ineligible (nine PCI, two PCI+cRT), leaving 42 randomized to PCI and 44 to
PCI+cRT. At planned interim analysis the study crossed the futility boundary for OS and was
closed prior to meeting accrual target. Median follow-up was 9 months. One-year OS was not
different between the groups: 60.1% [95% CI: 41.2–74.7%] for PCI and 50.8% [95% CI:34.0–
65.3%] for PCI+cRT (p=0.21). Three and 12-month rates of progression were 53.3% and 79.6%
for PCI, and 14.5% and 75% for PCI+cRT. Time to progression favored PCI+cRT, HR=0.53 (95%
CI: 0.32–0.87, p=0.01). One-patient in each arm had Grade-4 therapy related toxicity and one had
Grade-5 therapy related pneumonitis with PCI+cRT.

Author Manuscript

Conclusions—OS exceeded predictions for both arms. Consolidative RT delayed progression
but did not improve 1-year OS.
Keywords
Small cell lung cancer; extensive disease; thoracic radiation therapy; PCI; oligometastases

Introduction

Author Manuscript

SCLC comprises approximately 13% of lung cancers diagnosed in the United States. The
majority of patients with SCLC have metastatic disease.1 Primary therapy for ED-SCLC is
4–6 cycles of platinum-based chemotherapy followed by PCI in select patients. Although
response rates to chemotherapy are high at 60–70%, time-to-progression and median
survival are modest (4–6 months and < 10 months, respectively).1,2 Response and
improvement in survival is limited for second-line chemotherapy, particularly if progression
is within 30–90 days.3,4 PCI has been shown to decrease brain metastases and improve 1year OS in patients that respond to chemotherapy.5 The use of consolidative thoracic
radiation for ED-SCLC remains controversial even though it has been shown to improve
survival and locoregional control in both prospective randomized trials6,7 and retrospective
reviews.8,9

J Thorac Oncol. Author manuscript; available in PMC 2018 October 01.

Gore et al.

Page 3

Author Manuscript

RTOG-0937 was designed to address a select patient population with oligometastitc small
cell lung cancer (1–4 distant metastases) with consolidative RT to the locoregional thoracic
disease and active sites of metastases after chemotherapy. The underlying hypothesis was
that delaying progression of disease with radiation therapy will delay progression and
improve overall survival in this favorable patient population.
We conducted a randomized phase-II trial designed to evaluate PCI alone or PCI and
consolidative RT (PCI+cRT) to intrathoracic disease and limited extracranial metastases in
patients with oligometastatic small cell lung cancer.

Materials and Methods
Patient selection

Author Manuscript

NRG Oncology/RTOG 0937 is a two-arm randomized phase-II study designed to assess
whether the use of cRT in addition to PCI (PCI+cRT) would improve OS compared to PCI
alone for patients with ED-SCLC. Protocol approval was received from the Institutional
Review Board at each study site. Informed consent was obtained from each patient prior to
participation. Patients were randomly assigned to PCI or PCI+cRT to the intrathoracic
disease and residual metastases. Eligible patients had pathologically proven SCLC without
brain metastases and with 1–4 extracranial metastases at diagnosis based on CT scan of the
chest/abdomen and bone scan or PET/CT. Brain imaging was not required prior to
chemotherapy in the absence of symptoms but was required prior to randomization. Eligible
patients had PR or CR to 4–6 cycles of platinum based chemotherapy in a minimum of one
site of disease and no evidence of progression at any site. Restaging was required within
eight weeks of study entry. Imaging included CT of the chest/abdomen or PET/CT, bone
scan or PET, and MRI of the brain (or CT if MRI was contraindicated). Other eligibility
criteria included Zubrod PS 0–2, serum ALT and AST within 2.5×ULN and bilirubin
<1.5×ULN within one week prior to study entry for patients with liver metastases, serum
creatinine < 1.5×ULN for patients with renal or peri-renal metastases, absolute neutrophil
count ≥ 1,000 cells/mm3, platelets ≥ 75,000 cells/mm3 and hemoglobin ≥ 8 g/dl.

Author Manuscript

Treatment

Author Manuscript

All patients were to receive 25Gy PCI at 2.5Gy/fraction. In Arm 2, thoracic radiation
therapy to primary and involved regional nodes was required for all patients unless they had
had palliative radiation therapy to the primary at diagnosis. Radiation was delivered to postchemotherapy volumes including the site of the primary and involved nodal regions at
diagnosis. Metastases were treated if they did not have a CR to chemotherapy. The
recommended radiation dose to all extracranial sites was 45Gy delivered in 15 daily
fractions of 3Gy. 30–40Gy was acceptable if dose reduction was necessary to meet normal
tissue dose constraints. It was recommended that PCI be started concurrently with cRT
although sequential therapy was allowed at the discretion of the treating physician.
Patients were evaluated after therapy at two weeks, one, two, six, nine, and 12 months, every
six months for 2–3 years, then annually. CT of the chest/abdomen or PET/CT and brain
imaging were required at each visit starting at two months.
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The study was designed to detect a 33.7% relative reduction in the risk of death (HR, 0.663)
in the PCI+cRT as compared with PCI alone, at the significance level of 0.1 (1-sided) with
80% power. Based on the above, a total of 112 events and a sample size of 146 were
required. Adjusting for an ineligibility or insufficient follow-up rate of up to 5%, the final
targeted accrual was 154. Two interim analyses and a final analysis were planned for early
stopping for efficacy and futility when 37 and 75 deaths from both arms were observed. The
efficacy testing was based on the power family of test 10 with ∆=0, and the futility testing
boundary was based on Rule C (at a nominal significance level of 0.005) as proposed by
Freidlin and Korn.11 NRG Oncology/RTOG Data Monitoring Committee (DMC) oversaw
the interim monitoring. Patients were equally randomized into the two arms, based on
Zelen’s allocation scheme and stratified by response to treatment (CR vs. PR), number of
metastases (1 vs. 2–4), and age (<65 vs. ≥65, added on July 15, 2014). Age was added as a
stratification factor at the recommendation of the DMC when an unbalanced distribution
between treatment arms was observed without knowledge of efficacy information.

Author Manuscript

All outcome times were calculated from the date of randomization to the date of event or, if
no event, the date of last follow-up. For OS, the event is death due to any cause. The KaplanMeier method12 was used to estimate OS rates. For time to progression, the event was the
first occurrence of recurrence/progression of pre-existing disease (regardless of prior
response or treatment with RT) or development of new metastases. Death without failure
was considered as a competing risk. Actual rates of time to progression were estimated using
the cumulative incidence method13 by taking into account competing risks. The log-rank
test14 was used to compare OS event rates between treatments. The Cox regression model15
was used to compare the treatment differences. For time to progression, competing risk
events (death without progression) were censored at the time of competing event per the
cause-specific competing risks analysis method.16 Adverse events were evaluated using the
NCI CTCAE v4.0.

Results

Author Manuscript

The study opened to accrual March 18, 2010 and closed February 27, 2015. A planned
interim analysis indicated that the study crossed the futility boundary for the primary
endpoint and was closed prior to meeting the accrual target of 154 patients. The final
analysis was performed in August 2015 with a median follow-up of nine months, based on
all data received at NRG Oncology Statistics and DMC through July 15, 2015. 97 patients
were randomized from 57 participating sites. Eleven patients were ineligible and excluded
from analysis, nine patients randomized to PCI and two to PCI+cRT. Reasons for
ineligibility included failure to receive protocol therapy (two), inability to confirm eligibility
(two), testing completed outside the required time frame (four), brain metastases (one),
chemotherapy completed > eight weeks from study entry (one), and platelet count outside of
required range (one). 86 patients, 42 randomized to PCI and 44 to PCI+cRT, were included
in the analysis (Figure 1).
Pretreatment characteristics were evenly distributed with the exception of age (Table 1).
54.5% of patients randomized PCI+cRT and 38.6% to PCI arm were ≥ 65 (p=0.03). CR to
J Thorac Oncol. Author manuscript; available in PMC 2018 October 01.

Gore et al.

Page 5

Author Manuscript

chemotherapy (prior to study entry) in the primary lung tumor was 15.9% and PR 68.1%.
36% of patients had one metastasis, and 36%, 15.1% and 12.8% had two, three and four
metastases. The median time from diagnosis to start of radiation was 22 weeks for each
group. Median time from end of chemotherapy to start of radiation was 5.9 weeks and 6.9
weeks for PCI and PCI+cRT.
Among the PCI+cRT patients, two (4.5%) did not have TRT. Treating physicians withheld
radiation due to CR (1) and anticipated poor tolerance (1). Of the patients treated with cRT,
90.5% received thoracic radiation per protocol (30–45Gy). Two patients received less than
30Gy (22.5Gy and 24Gy) and two patients received > 45Gy (50 and 65Gy). 95.3% of all
patients received PCI per protocol.

Author Manuscript

At the time of this analysis, 51 deaths, including 22 with PCI, and 29 with PCI+cRT, were
reported. The one-year OS rates were 60.1% [95% CI: 41.2–74.7%] for PCI and 50.8%
[95% CI: 34.0–65.3%] for PCI+cRT (Figure 2). Median Survival was 15.8 months for PCI
and 13.8 months for PCI+cRT. The two-sided log-rank test p-value was 0.21, and the
unadjusted HR is 1.44 (HR favors PCI, 95% CI: 0.82–2.53). The majority of patients died of
disease progression (76.5%). Patients with CR to chemotherapy at all sites of disease
appeared to have better survival outcome than those with PR (any site), with a HR of 2.1
(HR favors CR, 95% CI: 0.97, 4.56) and p=0.06. Due to the limited sample of patients with
CR (all sites), PCI (10) and PCI+cRT (7), it was not possible to determine if PCI+cRT had a
differential treatment effect over PCI alone between CR and PR patients.

Author Manuscript

There were 32 patients with progression in the PCI arm, and 31 in the PCI+cRT arm. The
three-month and one-year rates of any progression were 53.3% [95% CI: 36.3–67.7] and
79.6% [95% CI: 60.6–90.2] for PCI, and 14.5% [95% CI: 5.8–27.0] and 75.0% [95% CI:
57.9–86.0] for PCI+cRT. The difference in the distribution of time to progression is
statistically significant (log-rank test p-value 0.01) with a hazard ratio 0.53 (HR favors PCI
+cRT, 95% CI: 0.32, 0.87) (Figure 3). There were only two and four deaths without
progression with PCI and PCI+cRT, respectively. Patients with CR (all sites) had a longer
time to progression than those with PR (any site), HR of 2.08 (95% CI: 1.04, 4.17) and
p=0.04. Median Progression Free Survival was 2.9 months [95% CI: 2.4, 3.7] for PCI and
4.9 months [95%CI: 3.4, 6.0] for PCI+cRT, p-value 0.0148.

Author Manuscript

First site of failure was in the sites present at diagnosis in 25 (78.1%) patients with PCI and
13(41.9%) with PCI+cRT (Table 2). First site of failure at sites of locoregional disease was
reported in 20 (62.5%) and 8(25.8%) of patients with PCI and PCI+cRT. New sites of
disease (not present at diagnosis) were reported in 10 (31.3%) of the 32 patients with PCI
and 19 (61.3%) of the 31 patients with PCI+cRT arm who progressed. First site of failure
occurred outside of radiation fields in 17 (54.8%) patients with PCI+cRT. In patients treated
with PCI+cRT there were ten (32.3%) first failures in the consolidative radiation fields
(other than brain), and four (12.9%) first failures in the brain only. One-year cumulative
incidence of brain metastases was 17% [95% CI: 6.6–40.2] and 18.5% [95% CI: 8.5–37.6]
with PCI and PCI+cRT. Brain was a component of first failure in six (19.4%) of the 31
patients with failures with PCI+cRT and in none of the 32 patients with PCI only.
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Grade-3 or greater adverse events regardless of attribution to protocol therapy occurred in
ten (23.8%) patients with PCI and 16 (36.4%) with PCI+cRT, p=0.24. Grade-3 or greater
toxicity attributed to therapy was reported in four (9.5%) patients with PCI and 11 (25%)
with PCI+cRT. Grade-3 toxicity with PCI+cRT included decreased blood counts, esophageal
symptoms, tachycardia, fatigue and respiratory symptoms. Grade-4 dyspnea and tracheal
stenosis was reported in one (2.4%) patient with PCI only and no Grade-5 toxicity attributed
to therapy with PCI. Two (4.5%) patients had Grade-4 and one (2.3%) Grade-5 toxicity
attributed to treatment with PCI+cRT. Grade-4 toxicity included hypoxia and respiratory
failure during treatment, and decreased platelets at 12 days post therapy. Grade-5
pneumonitis attributed to therapy was reported in one patient with PCI+cRT. This patient
received 42Gy to the chest with 37% of the lung receiving 20Gy or more, exceeding
protocol normal tissue dose constraints (Table 3).

Author Manuscript

Discussion

Author Manuscript

Thoracic radiation and PCI have been shown to decrease the incidence of locoregional
failures and brain metastases and improve survival in both LD-SCLC17,18 and ED-SCLC.5–7
Although multimodality therapy for LD-SCLC is standard of care, it remains controversial
for ED-SCLC. Patients with good response to chemotherapy and limited metastatic disease
are the most likely patients with ED-SCLC to benefit from multimodality therapy. NRG
Oncology RTOG 0937 was conducted to assess a potential survival advantage of
consolidative extracranial irradiation in patients with oligometastatic ED-SCLC. Although a
negative trial, there were several important findings: the first site of failure after
chemotherapy is likely to be in sites of presenting disease; radiation therapy to these sites
alters failure patterns; late radiation therapy without concurrent chemotherapy is not durable;
and, oligometastatic ED-SCLC survival approaches that of LD SCLC. Ineffective radiation
dose and schedule, advanced age and an imbalance in disease burden in the two groups all
likely contributed to lack of survival advantage with consolidative radiation therapy in this
trial.
Survival

Author Manuscript

Early randomized studies showed a survival advantage with thoracic radiation in addition to
chemotherapy for LD-SCLC.19,20 These early LD-SCLC studies did not include the routine
use of CTs and were conducted before the era of PET/CT and MRIs, therefore many patients
likely had unrecognized ED-SCLC. The routine use of PET/CT has been shown to increase
stage in 8–18% of patients.21,22 Thoracic radiation for ED-SCLC was supported by the
Jeremic trial reported in 1999 which showed a survival advantage in patients with ED-SCLC
treated with thoracic radiation. Despite compelling data, the routine use of thoracic radiation
in ED-SCLC has not been regarded as standard of care. However, many clinicians have
selectively used thoracic radiation and have published outcomes in several retrospective
reviews published since the initiation of the current trial. These retrospective reviews and
database analyses have shown improvement in survival with thoracic radiation (Table 4).6–9
The CREST trial, conducted in the Netherlands and the United Kingdon, was conducted
during the same time as the current trial. It included 495 patients with ED-SCLC randomly
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assigned to PCI or PCI and thoracic radiation (30Gy/10 fractions) after response to
chemotherapy. The number of metastases was not limited. OS at one year was the primary
endpoint. One-year OS was not different between the two groups with 33% (95% CI 27–39)
for thoracic radiation versus 28% (95% CI 22–34) for observation (hazard ratio [HR] 0.84,
95% CI 0.69–1.01; p=0.066). However, secondary analysis of two-year OS showed
improvement with thoracic radiation, 13% (95% CI 9–19) versus 3% (95% CI 2–8;
p=0.004). Toxicity was acceptable with 2% and 1.2% Grade-3 esophageal and pulmonary
toxicity.6

Author Manuscript

Additional analysis of CREST to identify patients who may have benefitted most from
thoracic radiation showed that thoracic radiation led to a significant difference in overall and
progression-free survival in patients who had residual intrathoracic disease after
chemotherapy. In these patients, the difference in OS was statistically significant (p=0.03;
HR 0.81; 95% CI: 0.66–0.98; stratified). They concluded that thoracic radiation should be
offered to patients with a good response or PR after chemotherapy, but not those with thorax
CR.23 There were too few patients in 0937 to perform this analysis.

Author Manuscript

The trial published by Jeremic et al in 1999 supported thoracic radiation for EDSLC in
patients with at least a PR to locoregional disease and a CR to extrathoracic sites with
chemotherapy.7 Similar to 0937, the majority of patients had one to two sites of metastases
at diagnosis, although this was not a requirement. Unlike NRG Oncology RTOG 0937,
patients with good response to first 3 cycles of chemotherapy received high dose radiation
therapy to the primary locoregional disease only with concurrent chemotherapy. Patients
were treated initially with three cycles of cisplatin and etoposide. Those with a CR or PR
locally and a CR at distant sites were treated with two cycles of carboplatin and etoposide +/
− concurrent hyperfractionated RT to the thorax (54Gy/36 fractions over 18 days). Both
groups received PCI. Median Survival (17 months versus 11 months, p=0.041), five-year
survival (9.1% versus 3.7%, p=0.041), and median time to local recurrence (30 versus 22
months, p=0.062) were improved in the RT group. The investigators did not describe a
difference between patients with and without residual disease in the chest after
chemotherapy. Distant metastatic rate remained high in both groups. The pattern of failure
relative to initial pattern of distant disease was not described.7

Author Manuscript

An important finding in NRG Oncology RTOG 0937 is that the median OS (15.8 months)
and one-year OS (60.1% 95%CI: 41.2, 74.7) in the PCI arm in 0937 exceeded what was
predicted with chemotherapy and PCI for ED-SCLC. For comparison, the median survival
with chemotherapy and PCI was 15.8 months compared to 8 months in the CREST trial.
Both of these trials calculated survival from randomization, which was after 4–6 cycles of
chemotherapy and restaging. In 0937 the median time from diagnosis to start of radiation
was greater than four months. The medians survival in the Jeremic trial with chemotherapy
and PCI alone for patients with CR to distant sites was 11 months from randomization which
was prior to starting chemotherapy. Additionally, the outcome of 0937 compares favorably
to the intergroup trial for LD-SCLC with concurrent RT to 45Gy at 1.8Gy daily fractions or
1.5Gy twice daily fractions with medians survival from randomization prior to
chemotherapy of 19 and 23 months respectively.24
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The design of 0937 intentionally included a favorable patient population with
oligometastases by rigorous staging at diagnosis and after chemotherapy. Perhaps a more
appropriate treatment for this patient population with low volume systemic disease is early
radiation concurrent with cycle three or four of chemotherapy in patients with a favorable
response to cycles one and two of chemotherapy followed by PCI, similar to the Jeremic
trial.

Author Manuscript

Concurrent chemotherapy and radiation has been shown to be superior to sequential
therapy.17 The importance of the early use of RT in LD-SCLC was demonstrated in the
National Cancer Institute of Canada Clinical Trials Group in 1993.25 Patients were
randomized to begin thoracic radiation on week 3 or 15 of chemotherapy. Patients without
progressive disease received PCI following chemotherapy and radiation. Progression free
survival (p=0.036) and OS (p=0.008) were superior with early thoracic radiation.
Additionally patients with late radiation had a higher risk of brain metastases.25 A
subsequent meta-analysis was undertaken by De Ruysscher et al to identify time factors for
combined chemotherapy and radiotherapy that may influence OS.26 The time from first day
of chemotherapy to last day of RT (Start of chemotherapy to End of Radiation (SER)) was
the most important predictor of outcome. There was a significantly higher five-year survival
rate in the shorter SER arms (relative risk [RR] = 0.62; 95% CI, 0.49 to 0.80; P =.0003),
which was more than 20% when the SER was less than 30 days (upper bound of 95% CI, 90
days).20 For comparison the SER for 0937 was well over 150 days.
Failure Patterns

Author Manuscript

Brain failures are well described and reported, although extracranial failure patterns after
chemotherapy have not been reported in detail. It is intuitive that the most likely site of
failure after chemotherapy for ED-SCLC is in areas of measurable disease at diagnosis,
particularly sites without at CR to chemotherapy. In the landmark trial showing an
improvement in 1 year overall survival with PCI in patients with ED-SCLC published by
Slotman et al, the chest was the most likely site of progression.5 Persistent intrathoracic
disease was present in 75% of patients after chemotherapy and approximately 90% had
intrathoracic progression in the first year. The CREST trial, evaluating thoracic radiation
therapy following chemotherapy was a natural follow up to this trial.6 Unlike the CREST
trial, NRG Oncology RTOG 0937 included consolidative RT to distant metastases in
addition to thoracic radiation and is the first study to evaluate outcomes and report failure
patterns in patients with oligometastatic ED-SCLC.

Author Manuscript

Patients on 0937 were more likely to fail in in sites of disease present at diagnosis. Fewer
patients in the PCI+cRT arm had their locoregional disease as a component of first failure
(25.8% vs 62.5%). Progression at presenting sites of disease was higher with PCI (78.1%)
than PCI+cRT (41.9%). Similar to 0937, patients on the CREST trial had lower isolated
intrathoracic progression of 19.8% with thoracic radiation compared 46% in the observation
arm (p<0.0001).6 Likewise, local recurrence free survival in the Jeremic trial at five years
was 20% with RT and 8.1% with chemotherapy only (p=0.062).7 Early concurrent
chemotherapy and high dose radiation therapy in the Jeremic trial likely contributed
favorable local recurrence free survival. An unexplained finding in the current trial was more
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new sites of disease and first-failures in the brain with PCI+cRT compared to PCI alone.
There was not a clear explanation for this based on site, volume and number of metastases.
Higher brain failures and new sites of disease suggests that there was an unaccounted for
imbalance in systemic disease burden decreasing the likelihood of seeing a survival
advantage with PCI+cRT.

Author Manuscript

Although consolidative radiation to locoregional disease and residual metastases after
chemotherapy delayed progression at 3 months, this benefit was not durable. The 3-month
rate of progression was 53.3% with PCI and only 14.5% with PCI+cRT, although by 1 year
the progression rates were not different at 79.6% and 75%, respectively. A more aggressive
course of radiation therapy would have likely resulted in a more durable response. PCI
remains controversial in the treatment ED-SCLC despite a survival advantage at 1 year
demonstrated by Slotman et al5 and advantages of PCI in early trials with subset analysis of
patients with extensive disease.18 Adding to this controversy is a recent Japanese trial which
did not show a survival benefit with PCI.27 PCI has consistently been shown to be effective
for decreasing brain failures although it is not completely clear which patients will derive a
survival benefit. Extent of disease at diagnosis, response to chemotherapy and
immunotherapy are important considerations. Treatment of active extracranial disease is
likely to also play an important role as active extracranial disease will continue to seed the
brain after PCI.
Toxicity
NRG Oncology 0937 was closed early due to a futility analysis showing that it was unlikely
there would be a survival advantage in the study arm. Unfortunately, unofficial
communications and discussions have suggested that there was excess toxicity on this trial.
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Toxicity in 0937 was as anticipated with the therapy delivered (Table 3). Grade 3+ toxicity
was 23% for PCI and 36% for PCI+cRT, p=0.24. Grade-4 and 5 toxicity included
hematologic and pulmonary toxicity. There was one death attributed to protocol therapy.
This patient had radiation-induced pneumonitis. The radiation dose to normal lung exceeded
dose constraints required by protocol. This emphasizes the importance of careful attention to
minimizing normal tissue dose exposure to radiation. Toxicity in 0937 compares favorably
to toxicity reported other trials evaluating thoracic RT for ED-SCLC and LD-SCLC. Jeremic
et al reported 20% Grade-3 and 7% Grade-4 esophageal toxicity and 5% Grade-3
bronchopulmonary toxicity with radiation and similar to CREST.6,7 Future studies should
encourage or require use RT techniques such as Intensity Modulated Radiation Therapy
(IMRT) and Stereotactic Body Radiation Therapy (SBRT) to minimize dose to normal
tissues including bone marrow to minimize hematologic toxicity and improve tolerance to
systemic therapy.

Conclusion
Patients with ED-SCLC represent a diverse patient population with a wide range of
anticipated outcomes. There is not one appropriate treatment regimen for all patients. This
study was the first to prospectively evaluate the favorable population with oligometastatic
SCLC. Consolidation radiation therapy delayed progression and altered failure patterns in
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this population. Toxicity was as anticipated with the therapy delivered and similar to
published data. The lack of benefit seen with PCI+cRT in this very favorable cohort of
patients with ED-SCLC may be due to lack of optimal timing, dose and fractionation of
radiation therapy. This study has demonstrated that this favorable subpopulation of patients
with ED-SCLC has OS similar to patients with LD-SCLC. Future trials for this population
should focus on timing, dose, and fractionation of radiation therapy delivery.
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Figure 1.

CONSORT Flow Diagram

Author Manuscript
J Thorac Oncol. Author manuscript; available in PMC 2018 October 01.

Gore et al.

Page 13

Author Manuscript
Author Manuscript
Figure 2.

Overall Survival
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Time to progression
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Demographics
PCI
(n=42)
n (%)

PCI and Consolidative
RT
(n=44)
n (%)

Total
(n=86)
n (%)

60.5 (47 – 81)

66 (35 – 86)

63 (35 – 86)

< 65

30 (71.4%)

20 (45.5%)

50 (58.1%)

≥ 65

12 (28.6%)

24 (54.5%)

36 (41.9%)

Male

18 (42.9%)

21 (47.7%)

39 (45.3%)

Female

24 (57.1%)

23 (52.3%)

47 (54.7%)

0

21 (50.0%)

18 (40.9%)

39 (45.3%)

1

21 (50.0%)

25 (56.8%)

46 (53.5%)

2

0 (0.0%)

1 (2.3%)

1 (1.2%)

CR/CR

10 (23.8%)

7 (15.9%)

17 (19.8%)

CR/PR

5 (11.9%)

6 (13.6%)

11 (12.8%)

PR/PR or Stable

27 (64.3%)

31 (70.5%)

58 (67.4%)

1

17 (40.5%)

14 (31.8%)

31 (36.0%)

2–4

25 (59.5%)

30 (68.2%)

55 (64.0%)

Head and neck

4 (9.5%)

2 (4.5%)

6 (7.0%)

Gastrointestinal

1 (2.4%)

1 (2.3%)

2 (2.3%)

Liver

10 (23.8%)

10 (22.7%)

20 (23.3%)

Renal

1 (2.4%)

0 (0.0%)

1 (1.2%)

Adrenal

6 (14.3%)

11 (25.0%)

17 (19.8%)

Bone

11 (26.2%)

8 (18.2%)

19 (22.1%)

Distant lymph nodes

13 (31.0%)

10 (22.7%)

23 (26.7%)

0 (0.0%)

1 (2.3%)

1 (1.2%)

Patient or Tumor Characteristic
Age
Median (Range)

Gender

Zubrod Performance Status

Author Manuscript

Response to initial treatment
(locoregional/metastases)

Number of metastatic lesions

Lesion locations†

Author Manuscript

Skin
Contralateral lung
Other location

3 (7.1%)

6 (13.6%)

9 (10.5%)

13 (31.0%)

21 (47.7%)

34 (39.5%)

†

Patients may have more than one site; percentages will not add to 100.
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Failure Patterns
PCI
(n=32)
n (%)

PCI and Consolidative
RT
(n=31)
n (%)

First failure at site of disease present at diagnosis

25 (78.1%)

13 (41.9%)

Locoregional disease as first failure

20 (62.5%)

8 (25.8%)

First failure brain
Failure at any time at new site

0 (0.0%)

6 (19.4%)

10 (31.3%)

19 (61.3%)
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Grade 3+ toxicity related to therapy.

Author Manuscript

Toxicity

PCI
N=42

PCI+cRT
N=44

Anemia

1

1

Tachycardia

0

1

Retinal Detachment

0

1

Gastrointestinal*

1

5

Fatigue

1

3

Lung Infection

0

2

Metabolism#

0

3

Muscle Weakness

0

1

Nervous System

1

1

Respiratory (grade 3)

0

2

Respiratory (Grade 4)

1

1

Respiratory (Grade 5)

0

1

Hypotension

0

2

Decreased Platelets
(grade 4)

0

1

Other**

1

4

*
Diarrhea, dyspepsia, dysphagia, esophagitis, nausea
#

Hyperglycemia, anorexia, dehydration

**

Decreased lymphocytes, decreased white blood cells
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Type

PhIIr
(n=86)

PhIIIr
(n=109)

Phase IIIr
(n=495)

Single institution Retrospective
(n-119)

Regional Database
(n=4782)

Study

RTOG 0937

Jeremic 1999

CREST 2015

Zhu 2011

Ou 2009

Variable

Variable

All patients with EDSCLC with ChT Response

All Patients with EDSLC with CR to DM with 3
cycles of ChT

1–4 metastatic lesions RT after ChT response

Patient Selection

8 mos
4 mos

ChT

19.3 mos

ChT
ChT/RT

17 mos

7.5 mos

ChT
ChT/RT
40–60 Gy 1.8–2Gy/Fx

11.8 mos

11 mos

ChT
ChT–>RT
30 Gy at 3Gy/fx

17mos

15.8 mos

ChT
ChT–>Cht/RT
54 Gy at 1.5Gy/fx

13.8 mos

Med Survival

ChT–>RT 45 Gy at 3Gy/fx

Treatment

Prospective and retrospective trials evaluating consolidative radiation therapy for ED SCLC

16.2%

27.8%

NA

28% (NS)

33%

46%

65%

60.1%

50.8%

1 year OS

3.8%

9.3%

17%

35%

3%

13%

28%

38%

NA

2yr OS

NA

5.1%

7.1%

NA

3.7%

9.1%

NA

5 yr OS
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p<0.0001

p=0.014

p<0.0001

p=0.041

NS
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